Haemophagocytic lymphohistiocytosis (HLH) constitutes a spectrum of immunological disorders characterized by uncontrolled immune activation and key symptoms such as fever, splenomegaly, pancytopenia, haemophagocytosis, hyperferritinaemia and hepatitis. In genetic or primary HLH, hyperactivated CD8 1 T cells are the main drivers of pathology.
Introduction
Haemophagocytic lymphohistiocytosis (HLH) is an increasingly recognized but incompletely understood hyperinflammatory syndrome occurring in children and adults. Characteristic symptoms include fever, hepatosplenomegaly, pancytopenia, hyperferritinaemia, coagulopathy and haemophagocytosis, arising in the event of a severe cytokine storm [1, 2] . Without a timely diagnosis and appropriate, often aggressive, therapy, the disorder is generally lethal. Hereditary, so-called primary, HLH is caused by harmful mutations in genes involved in the granule-mediated cytotoxic function of CD8 1 T cells and natural killer (NK) cells [3] . Acquired, secondary HLH is clinically similar to primary HLH but associated with various medical conditions, such as infections, malignancies, metabolic disorders, immunodeficiencies and autoimmune or autoinflammatory diseases [4] , the latter category often referred to as 'macrophage activation syndrome' (MAS).
Infections with herpesviruses such as Epstein-Barr virus and cytomegalovirus are considered the principal triggering factors of HLH [5] [6] [7] . Animal models have designated CD8 1 T cells and their excess secretion of interferon (IFN)-g as the main culprits in the pathogenesis of primary HLH. The aberrantly activated T cells infiltrate multiple organs, inducing lifethreatening immunopathology and driving uncontrolled systemic inflammation [8] [9] [10] [11] . Conversely, models of secondary HLH suggest that different mechanisms may underlie the pathogenesis of this subtype. In cytosinephosphatase-guanosine (CpG)-mediated secondary HLH, CD8 1 T cells were only mildly activated and dispensable for disease development [12] . In fact, T cells and adaptive immunity altogether were redundant in this model. The role of IFN-g was found to depend upon the activity of interleukin (IL)-10, being either pathogenic or largely redundant, with the exception of mediating anaemia [12, 13] . A similar absence of lymphoid involvement was described in two transgenic mouse models of secondary HLH [14, 15] . In a model of virus-associated secondary HLH that we have described recently (illustrated in Supporting information, Fig. S1 ), IFN-g was not required for HLH development; moreover, disease was worsened and a more complete spectrum of HLH symptoms developed in IFN-g-deficient mice. Thus, the model represents a tool to unravel IFN-g-independent pathways of HLH pathogenesis, as reported recently in IFN-g receptor 1/2 (R1/2) or signal transducer and activator of transcription 1 (STAT-1)-deficient patients [16] [17] [18] [19] . Additionally in this model, CD8
1 T cells were highly activated but dispensable in disease development, as their depletion did not mitigate HLH disease [20] . In contrast, the absence of CD8
1 T cells resulted in augmented viral proliferation, appointing T cells as an essential defence in virus-associated secondary HLH [20] . Also in patients, recent data suggest a discrepancy between primary and secondary HLH on the basis of T cell activation and differentiation patterns. Patients with primary HLH possessed more highly activated effector CD8 1 cells and a unique cytotoxic CD4 1 T cell signature compared to patients with secondary HLH. Viral infections were shown to shift the pattern of CD8 1 T cell activation in secondary HLH to overlap partially with the T cell phenotype observed in primary HLH [21, 22] . Thus, both animal and human data indicate that the lymphoid compartment is activated differentially and may play divergent roles in the pathogenesis of primary and secondary HLH. Additionally, secondary HLH has been reported to develop in patients lacking functional T cells, including severe combined immunodeficient (SCID) patients [23] . These intriguing findings urged us to investigate further the pathogenic or regulatory roles of different T cell populations in the development and progression of virus-associated secondary HLH, as well as potential therapeutic strategies to target these cell populations.
Using the mouse cytomegalovirus (MCMV)-induced animal model of secondary HLH [20] , we found the T helper (Th) cell population to be skewed towards a proinflammatory Th1 phenotype. CD4
1 T cells, including regulatory T cells (T reg ), showed a marked activation profile. As opposed to reports in primary HLH [24] , T reg cell numbers were not reduced markedly in secondary HLH. Therapeutic targeting of T cells had no effect on the initiation or progression of the HLH syndrome, but instead affected the rate of viral proliferation negatively, confirming the essential role of T cells in viral control. Not only T cells, but also B cells were dispensable for disease induction. To preserve control of the viral infection while simultaneously attenuating hyperinflammation in HLH, a therapeutic strategy was devised to target the highly activated CD25
1 T cells selectively, sparing quiescent T cells.
Although this strategy proved unsuccessful to alleviate HLH disease, it conserved viral control. Thus, rather than being lymphocyte-mediated, murine virus-associated secondary HLH appeared to operate through innate immune mechanisms, although the precise cell type could not be identified. Within the innate compartment, neutrophils were increased highly in blood and tissue, but their depletion was insufficient to prevent HLH development, suggesting no crucial role for neutrophils in disease pathogenesis. In-vivo depletion of T cells
Materials and methods

Mice, experimental design, viral infection and plaque assay
To deplete CD4 1 and/or CD8 1 T cells, a monoclonal anti-CD4-antibody (clone GK1.5) and/or monoclonal anti-CD8-antibody (clone YTS169, both Epirus Biopharmaceuticals, Utrecht, the Netherlands) were injected i.p. as a preventive treatment (300 lg/mouse on day 21 and 200 lg/mouse on day 2 p.i. in 100 ll PBS 5 early depletion) or as a curative treatment (300 lg/mouse on day 2 p.i., in 100 ll PBS 5 late depletion). Depletion was verified in blood and lymph nodes via flow cytometry using anti-CD4 (clone RMA-4) and anti-CD8a (clone 53-6.7). To target activated T cells, anti-CD25-antibodies (blocking function, clone 7D4, 500 lg/mouse or depleting function, clone PC61, 300 lg/mouse, both Epirus Biopharmaceuticals) were injected i.p. on day 2 p.i. Depletion was verified in blood and lymph nodes using anti-CD25 (clone 3C7). Control MCMV-infected mice were injected with an equal volume of PBS. Antibodies were administered using a randomized design so that animals from different experimental groups were co-housed to avoid cage effects.
In-vivo depletion of neutrophils
To deplete neutrophils, a monoclonal anti-lymphocyte antigen 6 complex, locus G (Ly6G)-antibody (clone 1A8) and monoclonal anti-glutathione reductase (Gr1)-antibody (clone RB6-8C5, both Epirus Biopharmaceuticals) were injected i.p. as a preventive treatment (250 lg/mouse on day 21 and day 2 p.i. in 100 ll PBS). Depletion was verified in blood and lungs via flow cytometry using anti-Ly6G-and anti-Gr1-antibodies on anti-Gr1-and anti-Ly6G-treated animals, respectively. Control MCMVinfected mice were injected with an equal volume of PBS or an isotype control [immunoglobulin (Ig)G2a, clone 2A3]. Antibodies were administered using a randomized design, co-housing animals from different experimental groups to avoid cage effects. 
Blood analysis and quantification of liver enzymes
Statistical analysis
Data with two experimental groups were analysed via a two-tailed non-parametric Mann-Whitney U-test. For comparison of three or more groups, a non-parametric Kruskal-Wallis test was performed, followed by Dunn's multiple comparison post-test. GraphPad Prism version 5.00 was utilized.
Results
T helper cells are skewed towards a Th1 response in MCMV-induced secondary HLH
To unravel the role of T cells in the pathogenesis of murine virus-associated secondary HLH, T helper (Th) cell profiles in MCMV-infected wild-type (WT) and IFN-g knock-out (KO) mice, which display a more severe and more complete HLH phenotype (Supporting information, Fig. S1 ), were investigated in different organs. The expression of specific Th cell lineage-defining transcription factors was assessed by quantitative real-time PCR: T-bet, GATA-3, ROR-gt and FoxP3 for, respectively, Th1, Th2, Th17 and T reg . Both in lymph nodes and spleen, the Th cell population appeared to be skewed towards a Th1 profile following MCMV infection, as evidenced by increased T-bet expression, while Th2-, Th17-and T reg -defining transcription factors were down-regulated (Fig. 1a) .
At the protein level, systemic production of typical Th1, Th2, Th17 and T reg cell-related cytokines was examined. Serum levels of IFN-g, IL-2, IL-12p70 and IL-18, all Th1-associated or Th1-stimulating cytokines, were elevated significantly in MCMV-infected mice (Fig. 1b) . With respect to Th2-associated cytokines, IL-4 was increased significantly in IFN-g KO mice, whereas levels of IL-5 and IL-13 remained unaltered post-infection (Fig. 1c) . The pattern of Th17-associated cytokines was ambiguous. Serum IL-17A was decreased in MCMV-infected WT and IFN-g KO mice, while IL-22 was increased. Levels of IL-23 seemed reduced in infected IFN-g KO mice, whereas no clear difference was observed in WT mice. IL-21 and GM-CSF could not be detected (detection limit 8Á81 and 15Á6 pg/ml, respectively) ( Fig. 1d and data not shown). Regarding T reg cellassociated cytokines, IL-10 was highly elevated postinfection. The increase was particularly pronounced in infected IFN-g KO mice. In contrast, serum TGF-b was decreased in infected mice, most significantly in WT mice (Fig. 1e) , exhibiting a pattern analogous to the expression of FoxP3 in spleen and lymph nodes (Fig. 1a) .
Taken together, the mRNA and protein data indicate that a Th1 response predominates both in WT and IFN-g KO mice with MCMV-associated secondary HLH.
The regulatory T cell population is not reduced in MCMV-induced secondary HLH
In murine primary HLH, hyperinflammation has been linked to an acquired T reg cell deficiency. T reg cells decline drastically during the fatal disease course, and as a consequence fail to suppress the aberrantly activated CD8
1 T cells and concurrent immunopathology [24] . Correspondingly, low T reg numbers were reported in untreated HLH patients [24] . As the T reg population in experimental MCMV-associated HLH seemed affected, i.e. decreased FoxP3 expression in spleen and lymph nodes, decreased secretion of TGF-b, but highly increased serum IL-10 ( [29] .
Together, these data suggest that MCMV-associated secondary HLH in WT and IFN-g KO mice does not result from a lack of T reg cell-mediated control of inflammation.
CD4
1 T cells are highly activated but dispensable in MCMV-induced secondary HLH As we reported previously, depletion experiments in the MCMV-induced HLH model appointed no significant pathogenic role to CD8 1 T cells, despite their hyperactivated phenotype [20] . However, CD4 1 T cells were also activated (Fig. 3a) . Nevertheless, typical HLHlike symptoms such as fever and cytopenia were unaffected by aCD4 or aCD4 1 8 treatment (Fig. 3b,c) . Other features were attenuated, although not significantly, exclusively in aCD4 1 8-treated mice. Hyperferritinaemia (Fig. 3d ) and liver dysfunction, measured by the plasma level of liver enzymes (Fig. 3f) , were tempered following co-depletion of CD4 1 and CD8 1 T cells. Interestingly, elevation of plasma soluble CD25 (sCD25) was abolished completely following aCD4 or aCD4 1 8 treatment. When both CD4 1 and CD8
1
T cells were depleted, sCD25 levels dropped below those measured in naive mice (Fig. 3e) , probably reflecting elimination of the cellular sources of sCD25. Conversely, aCD4 and aCD4 1 8 treatment resulted in increased activation of the residual CD4 1 and CD8 1 T cell population (Fig. 3g,h and data not shown), in line with previous findings following CD8 1 T cell ablation in this model [20] . Additionally, depletion increased splenic viral titres highly, particularly when CD4 1 and CD8 1 T cells were targeted together (Fig. 3k) .
The failure to control viral proliferation may explain, in part, the lack of efficacy of T cell depletion in the model. Additionally, when depleting antibodies were administered on day 2 post infection, so-called 'late' T cell depletion, similar results were obtained (Supporting information, Fig. S3 ). anti-CD4-and anti-CD8 antibodies, NI 5 not infected; ns 5 not significant (P ! 0Á05); *P < 0Á05; **P < 0Á01; ***P < 0Á001; Kruskal-Wallis with Dunn's post-test. Depicted data are from one experiment.
In conclusion, neither early nor late ablation of CD4 1 and/or CD8 1 T cells was sufficient to inhibit development and propagation of the HLH-like syndrome in MCMVinfected mice, indicating that T cells play no major role in the pathogenesis of this model. They are, however, an essential defence against persistent viral infections.
Development of MCMV-induced secondary HLH in SCID mice
As CD8 1 and CD4 1 T cells appeared to play a minor role in disease induction and propagation, we next investigated whether any adaptive lymphocytes were required for development of MCMV-associated HLH. To this end, SCID mice, lacking functional B and T cells, were inoculated with MCMV. Disease developed more slowly in MCMVinfected SCID mice, evidenced by more gradual progression of weight loss (Fig. 4a) and onset of hypothermia on day 9 post-infection (Fig. 4c) . Nonetheless, characteristic HLH-like symptoms such as fever, mild lymphadenopathy, anaemia, haemophagocytosis and decreased NK cell numbers developed (Fig. 4b,d ,f-h). Thrombocytopenia was absent (Fig. 4e ). These data demonstrate that nonlymphoid cells are sufficient to induce most features of HLH, suggesting an innate mechanism of pathogenesis.
CD25-targeting therapy does not fully ameliorate disease in MCMV-induced secondary HLH
As CD4 1 and/or CD8 1 T cell depletion had little effect on disease development, but favoured viral replication adversely, it appears that total T cell elimination is not a safe strategy in virus-associated secondary HLH. A less drastic intervention would be to target aberrantly activated T cells specifically to halt hyperinflammation, while conserving part of the T cell population to respond to the viral threat. To this end, two clones of anti-CD25 antibodies were used that either deplete CD25 high -expressing cells or block CD25 signalling, depriving target cells of the vital, stimulatory IL-2 signal. In murine primary HLH, overexpression of CD25 on CD8
1 T cells was shown to reverse the IL-2 consumption hierarchy, which is essential in regulating the magnitude of immune responses [24] . This same observation was made in MCMV-infected WT and IFN-g KO mice in lymph nodes (Fig. 5a,b) , spleen and lung (data not shown). Hyperactivated CD8 1 T cells increased their expression of CD25, surpassing that of T reg cells, thereby consuming the available IL-2, escaping immunosurveillance and feeding inflammation [24] . By targeting these CD25 high -expressing cells selectively, homeostasis could possibly be restored to limit immunopathology.
Blocking (clone 7D4) or depleting (clone PC61) anti-CD25-antibodies (aCD25) were administered to WT mice on day 2 following MCMV infection. Depletion (clone PC61) was confirmed in lymph nodes (Fig. 6b ) and lung (data not shown). Remarkably, 'blocking' clone 7D4 mediated a similar level of depletion (Fig. 6b) . The antibodies did not improve weight loss post-infection (Fig. 6a) , nor altered the occurrence of lymphopenia, thrombocytopenia, anaemia or haemophagocytosis (Fig. 6c-f) . As the treatment started on day 2 post-infection, no effect could be observed on the degree of fever (data not shown). Plasma ferritin and sCD25 were not reduced by aCD25 treatment (Fig. 6g,h ) and the drop in lung NK cells was not counteracted (Fig. 6i) . As anticipated, specific targeting of CD25 1 cells and not overall T cells preserved control over the viral infection, as viral titres did not differ between treated or untreated mice (Fig. 6k) . Contrary to what was expected, however, aCD25 treatment was unable to normalize the IL-2 consumption hierarchy (Fig. 6j) , which could explain the lack of therapeutic efficacy.
Given that MCMV-infected IFN-g KO mice showed higher expression levels of CD25 than WT mice (Fig. 2b) , we also tested aCD25 treatment in IFN-g KO mice, as this might prove more effective. However, the treatment did not reduce weight loss post-infection (Supporting information, Fig. S4a) , nor repressed the development of pancytopenia, haemophagocytosis, hyperferritinaemia, elevated plasma sCD25, decreased NK cell numbers or splenomegaly (Supporting information, Fig S4c-i) , an HLH symptom uniquely present in the absence of IFN-g [20] . Analogous to the findings in WT mice, the IL-2 consumption hierarchy was not restored by aCD25 treatment (Supporting information, Fig. S4k ), despite adequate depletion of CD25 1 cells in lymph nodes (Supporting information, 
Neutrophils are highly increased but play no role in development of MCMV-induced secondary HLH
As adaptive immunity T and B cells appeared to play a limited role in the pathogenesis of murine virus-induced secondary HLH, we turned our focus towards the innate immune compartment. During active disease, neutrophil numbers were highly increased in blood and tissue ( Fig. 7a-c) , both in infected WT and IFN-g KO mice.
Neutrophils are not only an important first line of defence against invading pathogens, initiating the earliest phases of inflammation, they are equally known to cause abundant organ damage in several autoimmune and autoinflammatory diseases, among others by the formation of neutrophil extracellular traps [30] . Considering their striking expansion following MCMV infection, these deleterious effects may contribute to the aberrant immune responses and tissue damage observed in the mouse model of secondary HLH. To investigate this hypothesis, two monoclonal antibodies targeting neutrophils (anti-Gr1 and anti-Ly6G) were administered to the mice on day 21 prior to MCMV infection, in order to prevent the development of HLH. Preventive treatment with anti-Gr1 could not reduce neutrophil numbers adequately (data not shown), while antiLy6G administration resulted in a pronounced depletion of neutrophils in blood as well as in lung tissue (Fig. 7b,c) . Nonetheless, the absence of neutrophils did not alter the development or severity of the HLH-like syndrome in MCMV-infected mice. Weight loss, fever, lymphopenia, thrombocytopenia, anaemia, hyperferritinaemia and hepatitis were undiminished in neutrophil-depleted mice (Fig. 7d-h) , indicating that the pathogenesis of murine virus-associated secondary HLH is independent of this cell type.
Discussion
Animal models of HLH have contributed greatly to our current knowledge of the mechanisms driving disease pathogenesis and have paved the way towards targeted therapy [31, 32] . However, as the diversity of these animal NI 5 not infected; ns 5 not significant (P ! 0Á05); *P < 0Á05; **P < 0Á01; ***P < 0Á001; Kruskal-Wallis with Dunn's post-test. Depicted data are from one experiment. models is great, given the heterogeneous nature of the underlying aetiologies of HLH, models of primary and secondary HLH often report conflicting data. This allows us to hypothesize that subtypes of HLH may be distinguished from other subtypes by a divergent pathogenesis [33] . In particular, differences in the role of specific T cell subsets requires further exploration. Primary HLH models are unanimous in that CD8 1 T cells are a crucial pathogenic factor, whereas CD4
Non-adaptive immune pathogenesis in HLH
1 T cells are dispensable [8, 10, 11] . However, in murine secondary HLH, both CD8 1 and CD4
1 T cells appear redundant [12, 14, 15] . In the current study, Th cell profiles were examined during murine cytomegalovirus (MCMV)-induced secondary HLH, including assessment of the regulatory T cell compartment. The CD4 1 and CD8 1 T cell dependency of the model was studied, as well as the requirement for adaptive immunity and the importance of IL-2 consumption homeostasis, dictated by gradations in the expression of CD25 on activated T cells. CD25-targeting therapy was evaluated for its efficacy in virus-associated secondary HLH. Lastly, the focus was turned towards the innate immune compartment, observing striking increases in neutrophil numbers during active HLH-like disease. Despite their abundance, targeted depletion experiments revealed no crucial role for these polymorphonuclear cells in the pathogenesis of the model.
Based on the expression of Th cell lineage-defining transcription factors and the serum concentration of Th cell-associated cytokines, the immune response in MCMVassociated secondary HLH appeared to be predominantly Th1-orientated. This Th1 signature parallels observations in HLH patients. Compared to healthy controls, levels of IFN-g and IL-12, important Th1-related cytokines, are often highly elevated in primary and secondary HLH, whereas levels of IL-4, a Th2-associated cytokine, are reported as undetectable, normal, decreased or only slightly increased [34] [35] [36] [37] , signifying domination of Th1 over Th2 cytokines. Conversely, IL-10, an anti-inflammatory cytokine produced by T regs which antagonizes Th1 cytokines, was also highly increased post-infection. This was remarkable considering the reduced serum levels of TGF-b, another important T reg cytokine, and concurrent decreased transcription of FoxP3 in lymph nodes and spleen of infected animals, indicating a decline in T reg numbers or activity [27, 28] . However, flow cytometry did not reveal a pronounced drop in T reg cell percentage or absolute numbers, and T reg cell activation and proliferation markers were increased significantly post-infection, suggesting that T reg cells are not defective in MCMV-induced secondary HLH. In contrast, T reg dysfunction may be inherent in primary HLH, as the cells use granule-mediated cytotoxicity to kill activated, autologous cells when dampening immune responses [38, 39] . In addition to this inherent defect, primary HLH may result from an acquired T reg defect. During active murine primary HLH, the T reg cell compartment was found to be deprived of stimulatory IL-2 signals, causing a drastic decline in T reg numbers and affecting their immunoregulatory function [24] . Nonetheless, the serum IL-10 concentration is elevated highly in most primary HLH models [8, 11, 40, 41] . Correspondingly, augmented serum IL-10 is reported frequently in HLH patients [34] [35] [36] [37] , although disease may be associated with a marked reduction of T reg cells [24] . Therefore, rather than originating from T reg cells, the serum IL-10 present in HLH patients and mice probably emanates from macrophages, actively performing haemophagocytosis [42] , or even from NK [41] or CD8 1 T cells [43] . As we could not provide evidence previously for a role of CD8
1 T cells in the pathogenesis of MCMV-associated secondary HLH [20] , data contrasting the findings in primary HLH mouse models [8, 10, 11] , the present study focused on the CD4
1 T cell population and the overall role of T and B lymphocytes. Remarkably, although the activation pattern of CD4 1 T cells correlated closely to disease severity in WT and IFN-g KO mice, CD4
1 T cell depletion did not affect disease development or progression. In addition, combined targeting of CD4 1 and CD8 1 T cells indicated that T cells were not required for disease pathogenesis, while functional T and B cells were dispensable to induce HLH-like disease in MCMV-infected SCID mice. These observations are in line with other models of secondary HLH, reporting lymphocyte-independent mechanisms of action. In a CpG-induced model of macrophage activation syndrome (MAS), mice lacking T, B and NK T cells could still develop HLH [12] . Similarly, recombination activating gene 1 (Rag1) deficiency could not ameliorate HLH-like disease in HIF1a-transgenic mice [15] , and another humanized transgenic mouse model of MAS did not respond to ablation of T and/or B cells [14] . In patients, it was published recently that the degree of CD8 1 
and CD4
1 T cell activation could be a distinguishing feature between primary and secondary HLH, which may be used for rapid diagnostic purposes. T cell populations were activated markedly and effector-differentiated in primary HLH, while this signature was mainly absent in patients with secondary HLH. T cell activation in virus-associated secondary HLH was situated between the spectrum from non-virus-associated secondary HLH to primary HLH [21, 22] . Thus, in contrast with primary HLH, T cells do not appear to play a similar, dominant pathogenic role in secondary HLH, demonstrating that disease is not driven necessarily by over-activation of the adaptive immune system. One hypothesis speculates that over-stimulation of innate immune pathways, via excessive Toll-like receptor triggering [12, 42, 44] or hypersecretion of myeloid-related cytokines [14] , may underlie secondary HLH. In the humanized mouse model of MAS, anti-CD33-mediated elimination of myeloid cells reverted disease completely [14] . These observations are clinically relevant, as there is evidence of patients who develop HLH independently of T cells or in the absence of T cell activation [21] . Primary immunodeficient patients, including SCID patients, may present with HLH despite severe T cell deficiencies [23] . In these patients T cell-targeting therapy is contraindicated, as innate mechanisms are probably driving pathogenesis. Similarly, a subgroup of HLH patients was reported recently to carry gain-of-function mutations in NLRC4, which cause spontaneous inflammasome activation and excessive IL-18 production, driving systemic macrophage activation and HLH flares [45] . Targeted inhibition of IL-18 could control the HLH syndrome successfully in one intriguing case report [46] , demonstrating that innate immune defects can underlie HLH. Notably, serum levels of IL-18 were also increased highly in the MCMV-induced mouse model of secondary HLH.
As depletion of CD4 1 and CD8 1 T cells increased viral replication dramatically in the model, we hypothesized that selective targeting of hyperactivated, CD25 high -expressing T cells might be more suited to break hyperinflammation and restore immune homeostasis, while maintaining sufficient control over the viral infection by preserving part of the mature T cell population. In this attempt, a blocking clone (7D4, IgM antibody, operating predominantly via the complement pathway) and a depleting clone (PC61, IgG antibody, functioning via antibody-dependent cell-mediated cytotoxicity) were used [47] . To specifically target T cells in HLH is not a new idea. Daclizumab, a CD25-blocking antibody similar to clone 7D4 used in the present study, has been administered successfully in three cases of paediatric and adult HLH, either as monotherapy or in combination with other immunosuppressants [48] [49] [50] . Additionally, daclizumab was shown to boost NK cell function in patients with multiple sclerosis, which could be of importance in HLH patients harbouring acquired NK cell defects. However in our model, no clear therapeutic effects of CD25 depletion or blockade were observed. This lack of effect could be associated to either the general lack of T cell dependency of our model or to a failure of the treatment to restore disruptions in the IL-2 consumption hierarchy. First, the success of CD25-targeting therapy in human HLH relies most probably on the elimination of activated T cells and a correction of elevated sCD25 serum levels. Thus, failure of the treatment in MCMV-associated secondary HLH may be associated with the finding that, in contrast to primary HLH models, there is no evidence for a pathogenic role of T cells. Possible application of anti-CD25 antibodies in the treatment of HLH should therefore be investigated further in animal models of primary, T celldependent HLH. Secondly, the failure of anti-CD25 therapy in our model could be explained by a lack of efficacy on the IL-2 consumption hierarchy. Expression levels of CD25, the IL-2 receptor a-chain, determine the intake of IL-2 by immune cells. During homeostasis, CD25 expression is highest on T reg cells, which suppress aberrant immune activation. When responding to an infection, CD25 expression on CD8 1 T cells increases transiently, redirecting IL-2 consumption away from T reg cells and initiating a temporary contraction of the T reg population, allowing effector CD8-mediated immune responses to expand. When the pathogen has been eradicated, the CD25 expression hierarchy is restored to its initial state. In murine primary HLH, however, reversion of the IL-2 consumption hierarchy was reported to persist. Decreased IL-2 production, increased levels of competitive sCD25 and heightened consumption of IL-2 by CD25 high -expressing CD8 1 T cells resulted in an IL-2-limiting environment, depriving T reg cells of crucial survival stimuli. The reversed CD25 hierarchy instead nourished activation of pathogenic CD8 1 T cells, stimulating immunopathology [24] .
Although CD8 1 T cells are not pathogenic players in MCMV-induced secondary HLH [20] , a similarly inverted IL-2 consumption hierarchy was observed which could not be overturned by anti-CD25 antibodies.
In conclusion, the presented data indicate that adaptive immune cells, and in particular T cells, were dispensable for the development of MCMV-associated secondary HLH, although they played a major part in anti-viral defences by controlling the viral proliferation rate. These findings highlight an important difference between primary and secondary HLH. Both animal models and human data indicate that adaptive lymphoid cells may be of minor importance in secondary HLH when compared to primary HLH. These insights appear to divide the spectrum of HLH into T cell-driven disease and haemophagocytic syndromes occurring in the absence of measurable T cell activation, and carry important therapeutic implications. Aggressive T cell-targeting drugs may only be indicated in patients with true 'lymphocytic' histiocytosis [21] . To assess the involvement of other cell populations in the development of 'non-lymphocytic' haemophagocytic histiocytosis, we focused here upon possible pathogenic contributions of neutrophils within the innate immune compartment. Neutrophil counts were increased highly during active disease, but preventive depletion of this cell type could not ameliorate any HLH-like symptoms in the mouse model. Thus, other innate immune cells may be involved in the pathogenesis of 'non-lymphocytic' haemophagocytic histiocytosis. Further research into this HLH subtype should focus upon the myeloid compartment, including monocytes and macrophages, but also upon different subsets of innate lymphoid cells including, but not limited to, NK cells and gd-T cells. Furthermore, attention should be devoted to non-haematopoietic cells such as fibroblasts, epithelial and endothelial cells, as they could play a thus far under-appreciated role in cytokine storm development, as addressed recently in MAS patients by our research group [51] , but also by others in severe influenza infections [52] [53] [54] . Fibroblasts and endothelial cells can contribute additionally to elevations in serum sCD25, attributed previously to excessive T cell activation in HLH, but shown recently to correlate poorly with T cell activation markers in patients with secondary HLH [21] .
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